BUND FINANCE

BUND FINANCE › Stocks › REGN

Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ · Stock price, chart and technical analysis

US$945.53-12.23 (-1.28%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$957.76
OpenUS$957.25
Day rangeUS$943.26 – US$972.00
52-week rangeUS$591.52 – US$991.73
Market capUS$97.80B
Volume704,317
50-day averageUS$821.61
200-day averageUS$748.97
Beta0.24
Last dividend per shareUS$3.70

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$16.1BUS$12.2BUS$13.1BUS$14.2BUS$14.3B
Net incomeUS$8.1BUS$4.3BUS$4.0BUS$4.4BUS$4.5B
EPS (diluted)71.9738.2234.7738.3441.48
Gross margin83.1%86.0%82.9%86.1%85.4%
Operating margin55.7%38.9%30.9%28.1%25.0%
Net margin50.3%35.6%30.1%31.1%31.4%
Free cash flowUS$6.5BUS$4.4BUS$3.9BUS$3.7BUS$4.1B
Total debtUS$2.7BUS$2.7BUS$2.7BUS$2.7BUS$2.7B
CashUS$2.9BUS$3.1BUS$2.7BUS$2.5BUS$3.1B

Compound annual growth: revenue -2.8% · net income -13.6% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E20.9x17.0x27.1x
EV / EBITDA14.6x14.0x16.5x
Operating margin29.5%—3.6%
Net margin28.5%—-0.0%
Debt / equity0.33—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Regeneron Pharmaceuticals, Inc.

SectorHealthcare
IndustryBiotechnology
CountryUS
CEOLeonard S. Schleifer
Employees15,410
IPO date1991-04-02

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally…

www.regeneron.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice